ILB-202

N/A

Report date: 2025/02/28 10:17:03

Base Information

Drug NameILB-202
Drug Alias NameILB-202ILB202
ClassificationCell and gene therapy > Gene therapyBiologics > Exosomes
Mechanisms of ActionNuclear factor NF-kappa-B complex inhibitorsGrowth hormone receptor agonists
TargetsNuclear factor NF-kappa-B complexGrowth hormone receptor
Therapy Area/IndicationsIntraoperative ComplicationsAcute Kidney Injury
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesIlias Biologics Inc
China Registration ClassN/A

Develop Information

Active CompaniesIlias Biologics Inc
Inactive CompaniesN/A
Active IndicationsIntraoperative ComplicationsAcute Kidney Injury
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A